This is a two-part multi-center clinical trial in participants with active IgG4-RD.
Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD.
Part 2 (Cohort 2) is a randomized, placebo-controlled, double-blinded (masked) trial phase to compare the effects of elotuzumab and prednisone to elotuzumab placebo and prednisone in participants with IgG4 RD.
Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2. Randomization in Part 2: 2 to 1, with approximately forty-two participants randomized to elotuzumab plus prednisone taper, and twenty-one participants randomized to placebo for elotuzumab plus prednisone taper.
The total duration of participant follow-up in this trial will be 48 weeks (11 months).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
IgG4 Related Disease IgG4-RD | Drug: elotuzumab Drug: placebo for elotuzumab Drug: methylprednisolone Drug: diphenhydramine Drug: acetaminophen Drug: famotidine Drug: prednisone | Phase 2 |
Immunoglobulin G4-Related Disease (IgG4-RD) is a chronic fibro-inflammatory condition that can affect virtually every organ system, including the pancreas, biliary tract, salivary and lacrimal glands, orbits, lungs, kidneys, meninges, pituitary gland, prostate and thyroid. It may also involve the retroperitoneum. This multi-organ immune-mediated condition, once regarded as a group of isolated, single-organ diseases, is now recognized to be an overarching, single-disease entity linked by common histopathological and immunohistochemical features.
IgG4-RD tends to afflict middle-aged to elderly individuals. Although IgG4-RD can affect a single organ at presentation, it is not uncommon for participants to present with or develop multi-organ disease. As the disease progresses, additional organs develop lesions and the cellular inflammation characterizing early disease moves toward a more fibrotic stage, causing major tissue damage, dysfunction and ultimately organ failure. It is unclear whether IgG4 itself is involved in the pathogenesis of the disease.
The goals of IgG4-RD treatment are to reduce inflammation and organ swelling and to prevent or reverse tissue fibrosis. No approved therapy exists for IgG4-RD.
This study will enroll adult participants who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for IgG4-RD, and who have active IgG4-RD with disease manifestations in at least two organ systems.
Primary study objectives:
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 75 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) |
Actual Study Start Date : | October 13, 2021 |
Estimated Primary Completion Date : | June 2024 |
Estimated Study Completion Date : | November 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred Taper
Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper.
|
Drug: elotuzumab
Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
Other Names:
Drug: methylprednisolone Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Solu-Medrol®
Drug: diphenhydramine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Benadryl®
Drug: acetaminophen Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Tylenol®
Drug: famotidine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: H2 blocker
Drug: prednisone Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
Other Name: corticosteroid
|
Experimental: Cohort 1b: Elotuzumab-Three-Month Regimen (Open-Label) + Pred Taper
Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.
|
Drug: elotuzumab
Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
Other Names:
Drug: methylprednisolone Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Solu-Medrol®
Drug: diphenhydramine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Benadryl®
Drug: acetaminophen Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Tylenol®
Drug: famotidine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: H2 blocker
Drug: prednisone Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
Other Name: corticosteroid
|
Experimental: Cohort 2: Arm A- Elotuzumab (Randomized) + Pred Taper
Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Forty-two participants will receive elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.
|
Drug: elotuzumab
Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
Other Names:
Drug: methylprednisolone Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Solu-Medrol®
Drug: diphenhydramine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Benadryl®
Drug: acetaminophen Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Tylenol®
Drug: famotidine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: H2 blocker
Drug: prednisone Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
Other Name: corticosteroid
|
Placebo Comparator: Cohort 2: Arm B-Placebo (Randomized) + Pred Taper
Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Twenty-one participants will receive placebo for elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.
|
Drug: placebo for elotuzumab
The placebo for elotuzumab is 0.9% sterile normal saline for injection.
Other Name: normal saline
Drug: methylprednisolone Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Solu-Medrol®
Drug: diphenhydramine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Benadryl®
Drug: acetaminophen Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: Tylenol®
Drug: famotidine Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Other Name: H2 blocker
Drug: prednisone Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
Other Name: corticosteroid
|
Safety measure defined as an adverse event or suspected adverse reaction that, in the view of either the investigator or sponsor results in any of the following outcomes (21 CFR 312.32(a)):
Efficacy measure, defined as:
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Individuals who meet all of the following criteria are eligible for enrollment as study participants:
May have newly-diagnosed or relapsing disease at screening
--Relapsing disease is defined as IgG4-RD that has previously been in remission but is now active again;
May be on treatment or off treatment for IgG4-RD at the time of screening
--If on treatment, must be willing to discontinue those other treatments before the Baseline (Day 0) visit;
Immunization with one of the FDA authorized or licensed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines is required for study entry
Exclusion Criteria:
Individuals who meet any of these criteria are not eligible for enrollment as study participants:
The following lab values as indicators of hepatic dysfunction:
Total bilirubin >two times the ULN unless caused by Gilbert's disease
---Gilbert's disease with total bilirubin > three times ULN
Any of the following laboratory tests at the Screening Visit:
Positive Quantiferon gold assay
Indeterminate Quantiferon gold assays must be repeated (with same or other interferon gamma release assay (IGRA) per local policy) and shown to be negative
---Alternatively, if the Quantiferon gold assay remains indeterminant, a participant must have a negative purified protein derivative (PPD)
Medical history or serologic evidence at Screening of chronic infections including:
IgG4-RD that is dominated primarily by advanced fibrotic lesions (°)
--Specifically, participants whose disease manifestations consist only of:
(°) Participants with these (Exclusion item 16) disease manifestations can be included, however, only if they have disease in 2 organ systems that is not of an advanced fibrotic nature and otherwise meet the Inclusion and Exclusion Criteria; or,
United States, Georgia | |
Emory Healthcare | Not yet recruiting |
Atlanta, Georgia, United States, 30322 | |
United States, Massachusetts | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Ana D. Fernandes 617-643-2140 Adfernandes@mgh.harvard.edu | |
Principal Investigator: John H. Stone, MD, MPH | |
United States, Minnesota | |
Mayo Clinic: Pulmonary and Critical Care Medicine | Not yet recruiting |
Rochester, Minnesota, United States, 55905 |
Study Chair: | John H. Stone, MD, MPH | Massachusetts General Hospital |
Tracking Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 4, 2021 | ||||||||||
First Posted Date ICMJE | June 8, 2021 | ||||||||||
Last Update Posted Date | October 15, 2021 | ||||||||||
Actual Study Start Date ICMJE | October 13, 2021 | ||||||||||
Estimated Primary Completion Date | June 2024 (Final data collection date for primary outcome measure) | ||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||
Change History | |||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Descriptive Information | |||||||||||
Brief Title ICMJE | Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) | ||||||||||
Official Title ICMJE | Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) | ||||||||||
Brief Summary |
This is a two-part multi-center clinical trial in participants with active IgG4-RD. Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD. Part 2 (Cohort 2) is a randomized, placebo-controlled, double-blinded (masked) trial phase to compare the effects of elotuzumab and prednisone to elotuzumab placebo and prednisone in participants with IgG4 RD. Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2. Randomization in Part 2: 2 to 1, with approximately forty-two participants randomized to elotuzumab plus prednisone taper, and twenty-one participants randomized to placebo for elotuzumab plus prednisone taper. The total duration of participant follow-up in this trial will be 48 weeks (11 months). |
||||||||||
Detailed Description |
Immunoglobulin G4-Related Disease (IgG4-RD) is a chronic fibro-inflammatory condition that can affect virtually every organ system, including the pancreas, biliary tract, salivary and lacrimal glands, orbits, lungs, kidneys, meninges, pituitary gland, prostate and thyroid. It may also involve the retroperitoneum. This multi-organ immune-mediated condition, once regarded as a group of isolated, single-organ diseases, is now recognized to be an overarching, single-disease entity linked by common histopathological and immunohistochemical features. IgG4-RD tends to afflict middle-aged to elderly individuals. Although IgG4-RD can affect a single organ at presentation, it is not uncommon for participants to present with or develop multi-organ disease. As the disease progresses, additional organs develop lesions and the cellular inflammation characterizing early disease moves toward a more fibrotic stage, causing major tissue damage, dysfunction and ultimately organ failure. It is unclear whether IgG4 itself is involved in the pathogenesis of the disease. The goals of IgG4-RD treatment are to reduce inflammation and organ swelling and to prevent or reverse tissue fibrosis. No approved therapy exists for IgG4-RD. This study will enroll adult participants who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for IgG4-RD, and who have active IgG4-RD with disease manifestations in at least two organ systems. Primary study objectives:
|
||||||||||
Study Type ICMJE | Interventional | ||||||||||
Study Phase ICMJE | Phase 2 | ||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Sequential Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment |
||||||||||
Condition ICMJE |
|
||||||||||
Intervention ICMJE |
|
||||||||||
Study Arms ICMJE |
|
||||||||||
Publications * |
|
||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||
Recruitment Information | |||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||
Estimated Enrollment ICMJE |
75 | ||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||
Estimated Study Completion Date ICMJE | November 2024 | ||||||||||
Estimated Primary Completion Date | June 2024 (Final data collection date for primary outcome measure) | ||||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria: Individuals who meet all of the following criteria are eligible for enrollment as study participants:
Exclusion Criteria: Individuals who meet any of these criteria are not eligible for enrollment as study participants:
|
||||||||||
Sex/Gender ICMJE |
|
||||||||||
Ages ICMJE | 18 Years to 70 Years (Adult, Older Adult) | ||||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||||
Contacts ICMJE | |||||||||||
Listed Location Countries ICMJE | United States | ||||||||||
Removed Location Countries | |||||||||||
Administrative Information | |||||||||||
NCT Number ICMJE | NCT04918147 | ||||||||||
Other Study ID Numbers ICMJE | DAIT AIG01 UM1AI144298 ( U.S. NIH Grant/Contract ) NIAID CRMS ID#: 38708 ( Other Identifier: DAIT NIAID ) |
||||||||||
Has Data Monitoring Committee | Yes | ||||||||||
U.S. FDA-regulated Product |
|
||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||
Responsible Party | National Institute of Allergy and Infectious Diseases (NIAID) | ||||||||||
Study Sponsor ICMJE | National Institute of Allergy and Infectious Diseases (NIAID) | ||||||||||
Collaborators ICMJE |
|
||||||||||
Investigators ICMJE |
|
||||||||||
PRS Account | National Institute of Allergy and Infectious Diseases (NIAID) | ||||||||||
Verification Date | October 2021 | ||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |